Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Ahmed Sawas, Helen Ma, Andrei R. Shustov, Pamela Hsu, Gajanan Bhat, Mark Acosta, Steven M. Horwitz, Owen A. O’Connor
Abstract
The BELIEF trial was an international study of belinostat in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) that led to FDA-approval for the disease. Herein, we present a subset analysis of patients with angioimmunoblastic T-cell lymphoma (AITL). Patients with R/R PTCL received belinostat 1000mg/m(2) intravenously every 21 days. The primary study endpoint was ORR by Cheson 2007 criteria. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of 129 patients treated, 22 patients were diagnosed with AITL. The ORR for AITL patients was 45.5%, with 18% achieving compete response. After a median follow up of 21.5 months, the median DOR, PFS, and OS were 13.6 months, 4.2 months, and 9.2 months, respectively. Common grade 3/4 adverse events were asthenia, fatigue, cytopenias, and septic shock. Single-agent belinostat induces clinically meaningful duration of response in patients with AITL and warrants further investigation in studies.